Commercial and clinical-stage systems · rone_robocath2019
R-One
R-One / R-One+ (next-generation robot)
1 / 6- Family
- Commercial and clinical-stage systems (commercial)
- Devices
- 0.014-in guidewire + rapid-exchange balloon/stent catheter; guide catheter manual. Next-gen: up to 5 devices simultaneously (press)
- Degrees of freedom
- 3 (gao2026_legobot via S8); 2 in li2024_design (conflict)
- Push
- Other drives
- Twist
- Rolling between rollers
- Tested up to
- Human
- Sim-to-real
- None found — No simulation-trained controller found for this robot.
Testing
- Highest level
- Human
- What was tested
- R-EVOLUTION 62 pts, 6 sites; registrational trial 145 pts (MicroPort, press); FIH of 2nd-gen 2026 (press)
- Key numbers
- R-EVOLUTION: technical success 59/62 (95.2%), clinical success 100%, 3 conversions (1 robot-related); robotic 19.9+-9.6 of 39.9+-14.6 min; operator dose -84.5% under apron (durand2023_evaluation Results, partial). 15 systems installed worldwide (medtechdive, web).
Mechanism
- Push (translation)
- other: motorised pads combining translation and rotation
- Twist (rotation)
- same pads (coupled with translation)
- Device range
- N.R.
- Target anatomy
- coronary (PCI); carotid stenting reported
Sensing and interface
- Force sensing
- none
- Leader and haptics
- no
- Imaging
- standard fluoroscopy; robot placed on table beside patient (official photo)
- Sterility
- single-use cassette (clear cover visible in company photo)
Size
- Footprint (mm)
- N.R.
- Mass (kg)
- N.R.
Simulation
- Simulation model
- none found
- Sim-trained controller
- none found
Versions
- Lineage
- R-One (CE 2019); R-One+; second-generation robot (up to 5 devices, first-in-human started 2026-01-27, 20 pts planned); R-ONE (NMPA 2023-12-08 via Cathbot JV)
Sources
- Evaluation of the R-One robotic system for percutaneous coronary intervention: the R-EVOLUTION study · EuroIntervention, 2023 · doi:10.4244/eij-d-22-00642 [durand2023_evaluation]
- Robot-Assisted Cardiovascular Interventions · Journal of the Society for Cardiovascular Angiography & Interventions, 2025 · doi:10.1016/j.jscai.2025.102568 [george2025_robot]
- Robotic Systems in Cardiovascular Interventions: Evolving Platforms and the Path Forward · Methodist DeBakey Cardiovascular Journal, 2025 · doi:10.14797/mdcvj.1652 [mandhumula2025_robotic]
Notes
- Notes
- Stereotaxis agreed in April 2026 to buy Robocath for up to US$45M (US$20M upfront + US$25M milestones incl. FDA clearance of next-gen system); closing 2026-07-07 (Stereotaxis 10-Q via web summary; medtechdive fetched). No FDA clearance for R-One. NMPA approval for R-ONE 2023-12-08 (MicroPort HKEX filing, via search summary).
This record
- Read level
- partial — abstract/partial + web
- Picture
- https://www.robocath.com/wp-content/uploads/2023/04/visuel2.png (listed by robocath.com WordPress media API; page https://www.robocath.com/product/) ↗ — licence: press image (Robocath; grade A
- Picture changes
- cropped (30,30)-(1620,1000) of 1920x1014
- Found by
- commercial: Search of commercial and clinical-stage systems.
- Data
- JSON · YAML:
records/robots/rone_robocath2019.yaml - Correction
- Suggest a correction [repository not created yet]